Pennsylvania SB190 establishes the Pharmaceutical Transparency Review Board to review high-cost prescription drugs and make recommendations for.
Pennsylvania SB190 creates the Pharmaceutical Transparency Review Board to review high-cost prescription drugs and develop recommendations for affordability. The board will analyze data from manufacturers, including costs, profit margins, and rebates. Manufacturers must report specific financial and operational details annually. The board will assess fees from manufacturers based on their market share. The Pharmaceutical Transparency Review Fund will support the board's activities.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.